Piezo Therapeutics key facts
- Operator of a drug delivery platform intended to replace lipid nanoparticles.
- It has raised $3.3M across 2 recorded rounds; the latest was Seed Round ($250K) in Jul 2025.
- Notable investors include Open Philanthropy Project, Georgia Research Alliance.
- Piezo Therapeutics has filed 2 Form Ds with the SEC since 2023, most recently Aug 2025 ($250K sold to 1 investors).
- Status: Privately Held (backing).
Who backs Piezo Therapeutics
2- ·Watch Piezo Therapeutics: the Monday email on marks, rounds and moves
Piezo Therapeutics funding rounds
2 roundsHow much has Piezo Therapeutics raised?
Piezo Therapeutics has raised $3.3 million in total; 2 of its rounds are on record. The largest on record was a $250,000 seed round in Jul 2025.
Piezo Therapeutics has filed 2 Form Ds with the SEC since 2023, most recently in Aug 2025 ($250,000 sold to 1 investor).
Piezo Therapeutics investors
2 investors are on record for Piezo Therapeutics, including Open Philanthropy Project and Georgia Research Alliance. The seed round in Jul 2025 drew 1 investor.
About Piezo Therapeutics
Operator of a drug delivery platform intended to replace lipid nanoparticles. The company's platform combines drug delivery technologies electric pulses and microneedles, allowing for the precise and controlled delivery of drugs to targeted areas of the body and thus improving the efficacy and safety of drugs and making them accessible to patients, enabling healthcare professionals to access improved RNA and DNA delivery and a wide range of nucleic acid medicines for vaccines, immunotherapies, therapeutic proteins, and gene therapies.
- Sector
- Healthcare
- HQ
- Atlanta, GA, United States
- Founded
- 2022
- Employees
- 7
- Website
- piezotx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Piezo Therapeutics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.